NASDAQ · IMTX
Immatics N.V.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for IMTX: Nov 16, 2026
Immatics N.V. Ordinary Shares is estimated to report earnings on 11/16/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.49. The reported EPS for the same quarter last year was $-0.49.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.49 | $-0.48 | $-0.50 | 2 |
| Dec 2026 | $-0.57 | $-0.49 | $-0.65 | 2 |
| Mar 2027 | $-0.51 | $-0.51 | $-0.51 | 1 |
| Jun 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · Fintel · RTTNews- Zacks · Oct 29, 7:35 AM EDTBristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesBristol Myers (BMY) delivered earnings and revenue surprises of +11.57% and +4.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Oct 26, 9:52 AM EDTImmatics N.V. Announces Updated Clinical Data for IMA402 and IMA203CD8Immatics N.V. announced updated clinical trial data from its ongoing phase 1b study with IMA402 PRAME TCR bispecific and its Phase 1 study with IMA203CD8 PRAME cell therapy. As of the June 1, 2026 data cutoff, 126 heavily pretreated patients received at least one infusion of IMA4
- Fintel · Oct 23, 8:51 AM EDTImmatics N.V. Announces Updated Phase 1 Data for IMA203CD8 with 51% Objective Response RateImmatics N.V. announced updated Phase 1 data for its IMA203CD8 PRAME TCR T-cell therapy across multiple solid tumor types. As of the August 7, 2026 data cutoff, 98 heavily pretreated patients across multiple advanced solid tumor types expressing PRAME that had undergone a median
- Fintel · Oct 14, 9:46 PM EDTStifel Initiates Coverage of Immatics N.V. at BuyFintel reports that on October 14, 2026, Stifel initiated coverage of Immatics N.V. (NASDAQCM:IMTX) (DB:4A3) with a Buy recommendation.Immatics N.V., based in Germany, operates in the biotechnology sector with a specialized focus on the discovery and development of T cell redirec
- RTTNews · Aug 25, 8:24 AM EDTImmatics Announces $150 Million Underwritten Offering; Stock Up(RTTNews) – Immatics N.V. (IMTX), a clinical-stage precision immunotherapies, announced that it has entered into an agreement to raise approximately $150 million through an underwritten public offering.
- RTTNews · Aug 18, 10:54 AM EDTImmatics Advances Anzu-cel Phase 3 Program; Reports Q2 Revenue Growth(RTTNews) – Immatics N.V. (IMTX), a global biopharmaceutical company focused on precision targeting of PRAME, provided a business update and reported second-quarter 2026 financial results, highlighting progress across its cell therapy and bispecific pipeline.
- Zacks · Jul 17, 10:59 AM EDTMRNA Advances Cancer Pipeline With New Immunotherapy StudyModerna doses the first U.S. participant in a phase I study of mRNA-4200, advancing its off-the-shelf cancer therapy pipeline beyond vaccines.
- Zacks · May 12, 8:25 AM EDTImmatics (IMTX) Reports Q1 Loss, Lags Revenue EstimatesImmatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 11:42 AM EDTACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales GrowthAcadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
- Zacks · May 7, 11:35 AM EDTMadrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpMDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
- Zacks · May 7, 11:30 AM EDTRXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YRecursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.
- Zacks · May 7, 11:15 AM EDTPrime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue EstimatesPrime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -15.99% and -45.13%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Immatics N.V. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.